Outcomes for patients with metastatic and recurrent osteosarcoma remain poor and a better understanding of the biology of this malignancy is critical to the development of prognostic biomarkers and novel therapies. The purpose of this study was to establish a biobank of osteosarcoma which has the potential of monitoring tumors dynamically with exosomes, to facilitate clinical and basic scientific research. The osteosarcoma biological specimen and clinical data of osteosarcoma were collected in Ruijin Hospital in two stages. In the first stage (2015–2017), the collection of tissue specimens and blood samples were performed at diagnostic biopsy, definitive surgery, recurrence and lung metastasis, according to the Children’s Oncology Group protocol. In the second stage (2017–2019), the tissue specimens were collected the same as before, but the blood samples were collected at the beginning of each MAP-I (methotrexate, cisplatin, doxorubicin, ifosfamide) chemotherapy cycle, and every 6 months after the last chemotherapy up to 3 years, according to our modified protocol, to dynamically monitor the status of possible alteration of gene expression profiling in the osteosarcoma. A total of 268 patients with osteosarcoma were enrolled in this study, 161 were men and 107 were women, with the mean age of 24.51 ± 15.58 years. Local recurrence occurred in 29 patients and lung metastasis in 51. The numbers of tissue and blood specimens reached 360 and 1023, respectively. 11 specimens were from recurrent osteosarcoma and 25 were from lung metastasis. The corresponding clinical and demographic data were collected in our electronic database. The osteosarcoma biobank built with our modified protocol mentioned above has the potential of monitoring tumors dynamically with exosomes and could provide specimens to the researches improving the biological understanding and outcome of this disease.

中文翻译：

---

建立动态骨肉瘤生物库：瑞金的经验。

转移性和复发性骨肉瘤患者的预后仍然很差，对这种恶性肿瘤生物学的更好了解对于预后生物标志物和新疗法的发展至关重要。这项研究的目的是建立一个骨肉瘤生物库，它具有利用外泌体动态监测肿瘤的潜力，以促进临床和基础科学研究。分两个阶段在瑞金医院收集骨肉瘤的生物学标本和骨肉瘤的临床资料。在第一阶段（2015-2017年），根据儿童肿瘤学组协议，在诊断性活检，确定性手术，复发和肺转移中收集组织标本和血液样本。在第二阶段（2017-2019年），与以前相同的方式收集了组织标本，但根据我们修改后的方案，血液样本是在每个MAP-1（甲氨蝶呤，顺铂，阿霉素，异环磷酰胺）化疗周期的开始以及最后一次化疗后每6个月（最多3年）收集的，以动态监测状态骨肉瘤中基因表达谱的可能改变 本研究共纳入268例骨肉瘤患者，男性161例，女性107例，平均年龄为24.51±15.58岁。局部复发29例，肺转移51例。组织和血液标本数量分别达到360和1023。11例来自复发性骨肉瘤，25例来自肺转移。在我们的电子数据库中收集了相应的临床和人口统计学数据。